Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;59(9):1209-1214.
doi: 10.1038/s41409-024-02360-w. Epub 2024 Jul 3.

Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status

Miquel Lozano  1   2   3 , Paola Charry  4 , Mar de Pablo-Miró  4 , María-Queralt Salas  5   6 , Carmen Martínez  5   7   6 , María Suárez-Lledó  5   6 , Francesc Fernández-Avilés  5   7   6 , Montserrat Rovira  5   7   6 , Joan Cid  4   5   7
Affiliations
Free article
Review

Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status

Miquel Lozano et al. Bone Marrow Transplant. 2024 Sep.
Free article

Abstract

Extracorporeal photopheresis (ECP) is a therapy that combines the collection of mononuclear cells by apheresis, the addition of a photosensitizer (8-methoxisoralen), the illumination of the product with ultraviolet A light, and the immediate infusion of the product to the patient. Initially developed and approved to treat T-cell cutaneous lymphomas, soon started to be used to treat graft versus host disease (GvHD) developed after allogeneic hematopoietic-cell transplantation. The high response rate of ECP in skin, ocular, oral, pulmonary, and liver forms of chronic GvHD, the steroid-sparing effect, and the improved overall survival of treated patients, made ECP one of the second-line treatments used to treat steroid-resistant acute and chronic GVHD. Recently, the development of new drugs for treating GVHD has changed the position of ECP in the therapy of GVHD and has started to be used in combination with drugs for increasing the response rate to the treatment in severe or resistant forms of acute and chronic GVHD. ECP remains an essential therapeutic resource in the management of patients with refractory acute and chronic GVHD.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transpl. 2020;55:1604–13. https://doi.org/10.1038/s41409-020-0826-4 . - DOI
    1. Salas MQ, Pedraza A, Charry P, Suarez-Lledo M, Rodriguez-Lobato LG, Brusosa M, et al. Post-transplantation cyclophosphamide and tacrolimus for graft-versus-host disease prevention after allogeneic hematopoietic cell transplantation from HLA-matched donors has more advantages than limitations. Transplant Cell Ther. 2023. https://doi.org/10.1016/j.jtct.2023.11.020 .
    1. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316:297–303. https://doi.org/10.1056/NEJM198702053160603 . - DOI - PubMed
    1. Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L. et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28:1–37. https://doi.org/10.1111/jdv.12311 . - DOI - PubMed
    1. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291:1207–11. https://doi.org/10.1056/NEJM197412052912301 . - DOI - PubMed